Regorafenib - an experimental drug improves survival rate of colorectal cancer patients, reveals phase III clinical trial study.
"For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them," says Dr. Grothey. "This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options."
Colorectal Cancer Screening with Colonoscopy
Colonoscopy is a widely used endoscopic procedure to screen individuals for colorectal cancer. It is very sensitive in detecting colorectal cancers.
Advertisement
Researchers tested regorafenib in a phase III, randomized, placebo-controlled trial, conducted simultaneously in the United States, Europe, Japan, Australia and China. They looked at survival outcomes in 760 patients whose cancer had progressed despite standard chemotherapy regimens. Regorafenib is a multi-kinase inhibitor, which has the effect of slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways that are activated in tumors.
Researchers found that patients with metastatic colon cancer who were treated with the drug showed a 29 percent increase in overall survival when compared to those treated with placebo. The median length of survival for patients treated with the drug increased from 5 months to 6.5 months, a statistically significant jump. Overall, regorafenib reduced patients' risk of dying from cancer during the trial by 23 percent.
![Quiz on Colon]( "Quiz on Colon")
Are you suffering from a migraine? It is possible that you have an unhealthy bowel. Strange - but true! This quiz is packed with information on the colon. Participate to learn more!
The trial, whose largest group of study participants in the United States was at Mayo Clinic, finished more than a year ahead of schedule.
"Patients with metastatic colorectal cancer who have failed all approved standard therapies have a poor prognosis," says Dr. Grothey. "This is the first and only agent in this setting that has demonstrated statistically significant overall survival benefit."
Source: Eurekalert
Quiz on Colon
Are you suffering from a migraine? It is possible that you have an unhealthy bowel. Strange - but true! This quiz is packed with information on the colon. Participate to learn more!
Advertisement
The trial, whose largest group of study participants in the United States was at Mayo Clinic, finished more than a year ahead of schedule.
"Patients with metastatic colorectal cancer who have failed all approved standard therapies have a poor prognosis," says Dr. Grothey. "This is the first and only agent in this setting that has demonstrated statistically significant overall survival benefit."
Source: Eurekalert
The Splendid Stomach - Animation
Stomach is the organ where food is mixed, stored and partially digested.
Advertisement
Advertisement
